T1	PROC 47 126	Estudio en fase I/II de la seguridad, tolerabilidad, farmacocinética y eficacia
T2	CHEM 141 151	relatlimab
#1	AnnotatorNotes T2	C4724799; Relatlimab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 156 165	nivolumab
#2	AnnotatorNotes T3	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	LIVB 169 196	participantes pediátricos y
T5	Age 183 194	pediátricos
T6	LIVB 197 212	adultos jóvenes
T7	Age 197 212	adultos jóvenes
T8	DISO 217 243	linfoma de Hodgkin clásico
#3	AnnotatorNotes T8	C1333064; Classical Hodgkin's Lymphoma; Neoplastic Process
T9	DISO 246 264	linfoma no Hodgkin
#4	AnnotatorNotes T9	C0024305; Lymphoma, Non-Hodgkin; Neoplastic Process
T10	CHEM 308 318	Relatlimab
#5	AnnotatorNotes T10	C4724799; Relatlimab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T11	CHEM 323 332	nivolumab
#6	AnnotatorNotes T11	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T12	LIVB 336 361	participantes pediátricos
T13	Age 350 361	pediátricos
T14	LIVB 364 379	adultos jóvenes
T15	Age 364 379	adultos jóvenes
T16	DISO 384 391	linfoma
#7	AnnotatorNotes T16	C0024299; Lymphoma; Neoplastic Process
T17	DISO 430 456	Linfoma de Hodgkin clásico
#8	AnnotatorNotes T17	C1333064; Classical Hodgkin's Lymphoma; Neoplastic Process
T18	DISO 459 477	linfoma no Hodgkin
#9	AnnotatorNotes T18	C0024305; Lymphoma, Non-Hodgkin; Neoplastic Process
T19	DISO 528 554	Linfoma de Hodgkin clásico
#10	AnnotatorNotes T19	C1333064; Classical Hodgkin's Lymphoma; Neoplastic Process
T20	DISO 557 575	linfoma no Hodgkin
#11	AnnotatorNotes T20	C0024305; Lymphoma, Non-Hodgkin; Neoplastic Process
T21	LIVB 604 632	Participantes de ambos sexos
T22	Age 633 651	menores de 18 años
T23	Age 685 711	igual o inferior a 30 años
T24	DISO 726 729	LHc
T25	LIVB 731 738	cohorte
#12	AnnotatorNotes T25	C0599755; Cohort; Population Group
T26	DISO 744 747	LNH
#13	AnnotatorNotes T26	C0024305; Lymphoma, Non-Hodgkin; Neoplastic Process
T27	LIVB 749 756	cohorte
#14	AnnotatorNotes T27	C0599755; Cohort; Population Group
T28	LIVB 767 780	Participantes
T29	DISO 785 788	LHc
T30	PROC 819 841	anatomopatológicamente
T31	Neg_cue 854 865	ausencia de
T32	Negated 866 875	respuesta
T33	PROC 890 927	tratamiento estándar de primera línea
T34	PROC 940 944	QTDA
T35	PROC 948 952	TACM
T36	LIVB 956 969	Participantes
T37	DISO 974 977	LNH
#15	AnnotatorNotes T37	C0024305; Lymphoma, Non-Hodgkin; Neoplastic Process
T38	PROC 1008 1030	anatomopatológicamente
T39	Neg_cue 1042 1053	ausencia de
T40	Negated 1054 1063	respuesta
T41	PROC 1078 1106	tratamiento de primera línea
#16	AnnotatorNotes T41	C1708063; First line treatment; Therapeutic or Preventive Procedure
T42	LIVB 1113 1126	participantes
T43	DISO 1139 1157	enfermedad medible
T44	PROC 1173 1184	TEP-FDG-TAC
T45	LIVB 1192 1200	cohortes
#17	AnnotatorNotes T45	C0599755; Cohort; Population Group
T46	DISO 1204 1207	LHc
T47	DISO 1210 1213	LNH
#18	AnnotatorNotes T47	C0024305; Lymphoma, Non-Hodgkin; Neoplastic Process
T48	PROC 1243 1254	Tratamiento
#19	AnnotatorNotes T48	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T49	CHEM 1269 1336	anticuerpo contra la proteína 4 asociada a linfocitos T citotóxicos
T50	CHEM 1355 1365	anticuerpo
#20	AnnotatorNotes T50	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T51	CHEM 1368 1478	fármaco dirigido específicamente a la coestimulación de los linfocitos T o a las vías de los puntos de control
T52	Neg_cue 1480 1499	con la excepción de
T53	PROC 1504 1516	tratamientos
#21	AnnotatorNotes T53	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T54	Negated 1504 1516	tratamientos
T55	CHEM 1529 1536	PD(L)-1
T56	PROC 1540 1551	Tratamiento
#22	AnnotatorNotes T56	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T57	CHEM 1563 1571	fármacos
#23	AnnotatorNotes T57	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T58	CHEM 1584 1589	LAG-3
T59	LIVB 1593 1606	Participantes
T60	PROC 1611 1647	trasplante autólogo de células madre
T61	PROC 1649 1653	QTDA
T62	DISO 1654 1658	TACM
T63	LIVB 1670 1683	Participantes
T64	PROC 1704 1732	alotrasplante de médula ósea
T65	DISO 1735 1771	enfermedad de injerto contra huésped
#24	AnnotatorNotes T65	C0018133; Graft-vs-Host Disease; Disease or Syndrome
T66	DISO 1773 1777	EICH
#25	AnnotatorNotes T66	C0018133; Graft-vs-Host Disease; Disease or Syndrome
T67	DISO 1812 1816	EICH
#26	AnnotatorNotes T67	C0018133; Graft-vs-Host Disease; Disease or Syndrome
T68	LIVB 1832 1845	Participantes
T69	DISO 1850 1873	enfermedades sistémicas
#27	AnnotatorNotes T69	C0442893; Systemic disease; Disease or Syndrome
T70	Neg_cue 1902 1904	no
T71	Negated 1905 1917	relacionadas
T72	DISO 1925 1931	cáncer
#28	AnnotatorNotes T72	C0006826; Malignant Neoplasms; Neoplastic Process
T73	LIVB 1957 1971	investigadores
#29	AnnotatorNotes T73	C0035173; Research Personnel; Professional or Occupational Group
T74	Spec_cue 1980 1993	comprometería
T75	Speculated 1997 2006	capacidad
T76	LIVB 2011 2023	participante
T77	Speculated 2029 2036	tolerar
T78	PROC 2040 2051	tratamiento
#30	AnnotatorNotes T78	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T79	LIVB 2067 2080	Participantes
T80	DISO 2085 2111	enfermedad autoinmunitaria
#31	AnnotatorNotes T80	C0004364; Autoimmune Diseases; Disease or Syndrome
